Highest development stage: Preclinical

Development status: Active (as of 2022)

Combination therapy

Mechanism of Action/Target pathogen: Inhibits class A and C β-lactamases; for use in combination with meropenem

Additional information: Synthetic compound. Inhibitor of serine beta-lactamases